BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 10823524)

  • 1. Difference in the responses after administration of granulocyte colony-stimulating factor in septic patients with relative neutropenia.
    Ishikawa K; Tanaka H; Nakamori Y; Hosotsubo H; Ogura H; Nishino M; Shimazu T; Sugimoto H
    J Trauma; 2000 May; 48(5):814-24; discussion 824-5. PubMed ID: 10823524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia.
    Ishikawa K; Tanaka H; Matsuoka T; Shimazu T; Yoshioka T; Sugimoto H
    J Trauma; 1998 Jun; 44(6):1047-54; discussion 1054-5. PubMed ID: 9637161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis.
    Schibler KR; Osborne KA; Leung LY; Le TV; Baker SI; Thompson DD
    Pediatrics; 1998 Jul; 102(1 Pt 1):6-13. PubMed ID: 9651406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial.
    Drossou-Agakidou V; Kanakoudi-Tsakalidou F; Sarafidis K; Taparkou A; Tzimouli V; Tsandali H; Kremenopoulos G
    Eur J Pediatr; 1998 Jul; 157(7):583-8. PubMed ID: 9686822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia.
    Kocherlakota P; La Gamma EF
    Pediatrics; 1997 Jul; 100(1):E6. PubMed ID: 9200380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia.
    Kocherlakota P; La Gamma EF
    Pediatrics; 1998 Nov; 102(5):1107-11. PubMed ID: 9794941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting effects of recombinant human granulocyte-macrophage colony-stimulating factor (CSF) and granulocyte CSF treatment on the cycling of blood elements in childhood-onset cyclic neutropenia.
    Wright DG; Kenney RF; Oette DH; LaRussa VF; Boxer LA; Malech HL
    Blood; 1994 Aug; 84(4):1257-67. PubMed ID: 7519479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia.
    Gillan ER; Christensen RD; Suen Y; Ellis R; van de Ven C; Cairo MS
    Blood; 1994 Sep; 84(5):1427-33. PubMed ID: 7520770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical effect of recombinant human granulocyte colony-stimulating factor on aplastic anemia].
    Asano S; Hirashima K; Yoshida Y; Takaku F; Miyazaki T; Omine M; Furusawa S; Abe T; Mori M; Arimori S
    Rinsho Ketsueki; 1990 Sep; 31(9):1456-62. PubMed ID: 1701008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study.
    Rackoff WR; Orazi A; Robinson CA; Cooper RJ; Alter BP; Freedman MH; Harris RE; Williams DA
    Blood; 1996 Sep; 88(5):1588-93. PubMed ID: 8781414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality.
    Presneill JJ; Waring PM; Layton JE; Maher DW; Cebon J; Harley NS; Wilson JW; Cade JF
    Crit Care Med; 2000 Jul; 28(7):2344-54. PubMed ID: 10921563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of maternal preeclampsia on recombinant human granulocyte colony-stimulating factor effect in neutropenic neonates with suspected sepsis.
    Zuppa AA; Girlando P; Florio MG; Cota F; Romagnoli C; Tortorolo G
    Eur J Obstet Gynecol Reprod Biol; 2002 May; 102(2):131-6. PubMed ID: 11950479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation.
    Shimazaki C; Uchiyama H; Fujita N; Araki S; Sudo Y; Yamagata N; Ashihara E; Goto H; Inaba T; Haruyama H
    Exp Hematol; 1995 Dec; 23(14):1497-502. PubMed ID: 8542937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo effect of recombinant human granulocyte colony-stimulating factor on phagocytic function and oxidative burst activity in septic neutropenic neonates.
    Ahmad M; Fleit HB; Golightly MG; La Gamma EF
    Biol Neonate; 2004; 86(1):48-54. PubMed ID: 15057022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte colony-stimulating factor serum and urine concentrations in neutropenic neonates before and after intravenous administration of recombinant granulocyte colony-stimulating factor.
    Calhoun DA; Lunøe M; Du Y; Hutson AD; Veerman M; Christensen RD
    Pediatrics; 2000 Feb; 105(2):392-7. PubMed ID: 10654961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization.
    McCawley LJ; Korchak HM; Douglas SD; Campbell DE; Thornton PS; Stanley CA; Baker L; Kilpatrick L
    Pediatr Res; 1994 Jan; 35(1):84-90. PubMed ID: 7510873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
    Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
    Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical observation of the salvage therapy using pegylated recombinant human granulocyte colony stimulating factor for grade IV neutropenia induced by concurrent chemoradiotherapy].
    Wu F; Wang H; Li N; Guo Y; Cheng Y; Liu Q; Yang X; Wan X; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):708-12. PubMed ID: 25564064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.